CFDE Data Portal | Search POLR2L

	Label	Description
	POLR2L Gene (Entity type)	ENSG00000177700 - RNA polymerase II, I and III subunit L
	POLR2L associations Collection (Entity type)	Associations for POLR2L_associations
	POLR2L associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	GSE158632 3 V 5 OXYQUINOLINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE120612 4 V 1 ETOPOSIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE120210 GSE120214 TBXT brachyury inhibition 4 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE242290 3 V 2 GLUTATHIONE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE119978 GSE180930 cisplatin 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE217552 fisetin 3 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE210655 3 V 2 CISPLATIN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS

POLR2L

ENSG00000177700 - RNA polymerase II, I and III subunit L

POLR2L associations

Associations for POLR2L_associations

POLR2L associations.tsv

A file from IDG as part of the Harmonizome project

GSE158632 3 V 5 OXYQUINOLINE HUMAN DN

A Gene Set from LINCS

GSE120612 4 V 1 ETOPOSIDE HUMAN UP

A Gene Set from LINCS

GSE120210 GSE120214 TBXT brachyury inhibition 4 v 0 human dn

A Gene Set from LINCS

GSE242290 3 V 2 GLUTATHIONE HUMAN DN

A Gene Set from LINCS

GSE119978 GSE180930 cisplatin 3 v 1 human dn

A Gene Set from LINCS

GSE217552 fisetin 3 v 2 human up

A Gene Set from LINCS

GSE210655 3 V 2 CISPLATIN MOUSE UP

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.